10.1016/j.pharmthera.2023.108373 26 CozziA.OrellanaD
Based on current human studies, such as the one by Laferrre et al., GHRP-2 does not appear to significantly alter macronutrient preference
Current Regulatory Status Neither CJC 1295 nor ipamorelin holds FDA approval for any human indication
Antibodies against PARP (ab191217), Caspase-9 (ab32539), Cyclin D1 (ab40754), CDK6 (ab124821), p21 (ab109520), Cyclin A2 (ab32386), Cyclin E1 (ab33911), ASNS (ab40850), GPX4 (ab125066), Ferritin (ab75973), TfR1 (ab214039), IREB2 (ab232994), RRM2 (ab57653), c-Myc (ab32072), NDUFV2 (ab183715), NDUFS3 (ab177471), NDUFS8 (ab170936), Grim19 (ab110240), SDHA (ab137040), SDHB (ab178423), UQCRB (ab190360), UQCRC2 (ab203832), UQCRFS1 (ab191079), COX IV (ab202554), ATP5A (ab176569), and TOMM20 (ab186735) were obtained from Abcam (Cambridge, MA)
Its powerful antioxidant properties are believed to combat oxidative stress, which can lead to premature ageing and skin damage
27 Jan 2020 Funding The research was supported by the Shanghai Municipal Commission of Health and Family Planning, Shanghai Shenkang Hospital Development Center, Shanghai Municipal Education Commission, National Natural Science Foundation of China, Shanghai Committee of Science and Technology, Xinhua Hospital of Shanghai Jiao Tong University School of Medicine, National Human Genetic Resources Sharing Service Platform, the National Key Research and Development Program of China, 111 Project, the Shanghai Municipal Science and Technology Major Project, Guangdong Key Project, and ZJ Lab
